| NCT06663137 | Open Label Study to Evaluate the Safety and Efficacy of NDV01 KIT in High Grade NMIBC | RECRUITING | PHASE2 | 2024-08-01 | 2026-08 | 2025-08 |
| NCT06011577 | Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD | TERMINATED | PHASE3 | 2023-08-17 | 2024-12-19 | 2024-12-19 |
| NCT05081167 | A Study to Assess the Efficacy and Safety of REL-1017 as Monotherapy for Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2021-06-02 | 2022-09-14 | 2022-09-13 |
| NCT04855760 | Safety of REL-1017 for Major Depressive Disorder | COMPLETED | PHASE3 | 2021-04-01 | 2023-07-27 | 2023-07-27 |
| NCT04855747 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) | TERMINATED | PHASE3 | 2021-03-30 | 2025-01-14 | 2024-12-31 |
| NCT04688164 | A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2021-01-08 | 2022-11-10 | 2022-11-01 |
| NCT03051256 | Safety, Tolerability, PK Profile, and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD | COMPLETED | PHASE2 | 2018-05-11 | 2019-09-30 | 2019-07-30 |
| NCT03638869 | Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of REL-1017 (d-Methadone) | COMPLETED | PHASE1 | 2015-08-31 | 2015-11-16 | 2015-11-16 |
| NCT03637361 | Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of REL-1017 (d-Methadone) | COMPLETED | PHASE1 | 2014-12-04 | 2015-06-02 | 2015-06-02 |